Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors
NCT06462222Phase 2Active, not recruiting
- Sponsor
- Guangzhou Medical University
- Start
- Jun 2024
- Primary completion
- Nov 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab, pemetrexed in leptomeningeal metastasis (LM), sponsored by Guangzhou Medical University. Started Jun 2024; status: active, not recruiting.
02
Drugs
toripalimabpemetrexed
03
Conditions
leptomeningeal metastasis (LM)
Beyond the preview
Go deeper on NCT06462222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06462222.